Study On The Use Of Aspirin Combined With Blood-activiating And Stasis-dissolving Chinese Patent Medicine For Patients With Stable Angina Pectoris

Object and Method:Object1. At some cadre retirement centers in Beijing, the medical records of patients with CHD were investigated ;2.To make case survey in these patients through interrogation;3. to select patients with SAP, those amount to 723 cases;Inclusive criteria: in accordance with the diagnostic criteria for SAP defined by WHO in 1981;Exclusive criteria: complicated with all kinds of infections, rheumatism , connective tissue diseases,malignant tumor,andsevere hepatic and renal dysfunction; Method1.Data of cases history and medicine were collected, input into the PC as Excel files form;2.Analysed by descriptive analysis and×2 test using SPSS13.0 software package;Results1. The usage rate of antiplate drugs, blood-activiating and stasis-dissolving Chinese Patent Medicine and antiplate drugs combined with blood-activiating and stasis-dissolving Chinese Patent Medicine was 70.8% (5l2cases), 54.5% (394cases) ,42.9% (310cases) seperately.2. The usage rate of antiplate drugs was higher in low age groups than high age group (P <0.05); The usage rate of blood-activiating and stasis-dissolving Chinese Patent Medicine was higher in high age group than low age group.Antiplate drugs combined with blood-activiating and stasis-dissolving Chinese Patent Medicine showed a same difference in different age group. But thers is no statistical difference between above 85 years group with 75- 84 years group.3. The usage rate of antiplate drugs was higher in female patients than male patients. The usage rate of blood-activiating and stasis-dissolving Chinese Patent Medicine was opposite.4.The patients who took antiplate drugs alone amount to 84 cases(11.6%), lower than that(202, 27.9%) who took blood-activiating and stasis-dissolving Chinese Patent Medicine alone, and that(310, 42.9%) who took antiplate drugs combined with blood-activiating and stasis-dissolving Chinese Patent Medicine. The other 127(17.6% ) patients didn't use antiplate drugs or blood-activiating and stasis-dissolving Chinese Patent Medicine. 5.There were 273 (69.3%) patients who took one blood-activiating and stasis-dissolving Chinese Patent Medicine, and 121 (30.7%)patients who took 2 or more .6.The usage rate of blood-activiating and stasis-dissolving Chinese Patent Medicine was different in this study, composite salvia miltiorrhiza (29.9%) was most, then followed by Ginkgo biloba eatracts(24.4%);Conclusions :1. For the useage of antiplate drugs to 723 patients with SAP, there were still great gap with the requirement of the treatment recommendations for CHD;2. There was no syndrome differentiation and treatment in most of blood-activiating and stasis-dissolving Chinese Patent Medicine ;3. It is urgent to standardize the application of antiplatelet drugs;4. It is necessary to further study on the guide of blood-activiating and stasis-dissolving Chinese Patent Medicine application.